


# VaccZyme™ *Salmonella typhi* Vi IgG ELISA: A test for polysaccharide response

Specific antibody response to polysaccharide antigens is an important part of immune system evaluation when immunodeficiency is suspected.<sup>1-3</sup> This includes assessment by vaccinating individuals with Pneumovax® and measuring the response to pneumococcal capsular polysaccharide (PCP).

The routine use of peptide-conjugated pneumococcal vaccines (e.g. Prevenar13®) has made the measurement and interpretation of response to Pneumovax challenging. Response to Pneumovax may be elevated due to recall of a Prevenar response which could mask an antibody deficiency.

Response to *Salmonella typhi* Vi (*S. typhi* Vi) can be used as an additional tool for assessing antibody production against a polysaccharide antigen.<sup>5-7</sup> *S. typhi* Vi polysaccharide vaccines are well-established for use in adults and children (>2 years old).



# VaccZyme™ *Salmonella typhi* Vi IgG ELISA: A test for polysaccharide response

The VaccZyme™ *Salmonella typhi* Vi IgG ELISA kit is designed to measure the ability of an individual's immune system to raise specific IgG antibodies against the virulence factor (Vi) of *Salmonella typhi*.

<b>Diagnostic Tool</b>	An additional tool to measure response to polysaccharide antigens in patients with suspected antibody deficiency
<b>Interpretation</b>	Easy interpretation based on a single cutoff value
<b>Quality and regulatory status</b>	CE marked and conforms to ISO13485:2016 and MDSAP requirements

Description	Code	Pack Size	Measuring Range	Assay Time
VaccZyme™ <i>Salmonella Typhi</i> Vi IgG ELISA kit	MK091	96 well	7.4 – 600 U/ mL	<2 hours

#### References

1. Bonilla FA, *et al.* J Allergy Clin Immunol 2015;136:1186-205
2. De Vries E, *et al.* Clin Exp Immunol 2012;167:108-19
3. Orange JS, *et al.* J Allergy Clin Immunol 2012;130:S1-24
4. Ochoa Grullon *et al.* Methods X 2020
5. Parker *et al.* J Immunol Methods. 2018; 459:1-10.
6. Kumarage. Heliyon 2017 ;3
7. Sanchez-Ramon Clin Immunol 2016;169:80-4



#### VaccZyme Panel

##### Protein Vaccine Response

Tetanus toxoid IgG response	MK010
Diphtheria toxoid IgG response	MK014

##### Peptide-Conjugated Vaccine Response

<i>Haemophilus influenzae</i> type B IgG	MK016
--	-------

##### Polysaccharide Vaccine Response

Pneumovax IgG response	MK012
Typhim Vi IgG response	MK091

To find out more contact your local office  
[www.bindingsite.com/contact](http://www.bindingsite.com/contact)

Vacczyme is a trademark of The Binding Site Group Ltd (Birmingham, UK).  
Pneumovax is a trademark of Merck & Co, Inc (Rahway, NJ, USA).  
Prevenar13 is a trademark of Pfizer, Inc, (PA, USA).

